Form 4: ARS Pharma CLO Granted 240,000 Stock Options

ARS Pharmaceuticals' Chief Legal Officer, Alexander A. Fitzpatrick, was granted 240,000 stock options with an exercise price of $11.49, vesting over 48 months.

Summary

• Alexander A. Fitzpatrick, Chief Legal Officer of ARS Pharmaceuticals, Inc. (SPRY), was granted 240,000 stock options.
• The stock options have an exercise price of $11.49 per share.
• The options were granted on January 2, 2026, and are exercisable from this date.
• The shares subject to the option will vest in a series of 48 equal monthly installments, measured from January 1, 2026.
• The expiration date for these stock options is January 1, 2036.
• Following this transaction, Alexander A. Fitzpatrick beneficially owns 240,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a positive for aligning management incentives with shareholder interests, but it is a routine compensation event and does not directly reflect on operational or financial performance, hence a moderately positive score.

Positives

• The grant of stock options aligns the Chief Legal Officer's long-term financial interests with those of the company's shareholders, incentivizing sustained performance.
• Equity compensation is a standard mechanism for attracting and retaining key executive talent.

Future Outlook

The vesting schedule for the stock options over 48 months from January 1, 2026, indicates a long-term incentive for the Chief Legal Officer, aligning their interests with the company's future performance and strategic objectives.

Industry Context

The grant of stock options to a key executive is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize talent, aligning management's long-term interests with shareholder value creation. This type of compensation is crucial for companies in sectors requiring significant long-term development and regulatory milestones.

Comparison to Industry Standards

• This type of equity grant is a common component of executive compensation packages across publicly traded companies, particularly in growth-oriented sectors like pharmaceuticals.
• While specific grant sizes vary based on company size, executive role, and performance metrics, the structure of a multi-year vesting schedule (48 months) is a widely accepted benchmark for long-term incentive plans, comparable to practices at companies like Moderna or BioNTech for their key executives.

Stakeholder Impact

• Shareholders benefit from increased alignment of executive incentives with long-term company performance, potentially leading to enhanced shareholder value.
• Employees may view this as a positive sign of executive commitment and stability within the company.

Next Steps

• The granted stock options will vest in 48 equal monthly installments, beginning January 1, 2026, subject to continued employment.

Key Dates

Keywords

ARS Pharmaceuticals, SPRY, Alexander A. Fitzpatrick, Chief Legal Officer, Stock Options, Insider Transaction, SEC Form 4, Executive Compensation, Equity Grant